Sevuparin

Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Notice to attend the AGM in Modus Therapeutics Holding AB (Publ)

Sevuparin receives Rare Pediatric Disease Designation from FDA for the treatment of children with sickle cell disease

Learn more about our ongoing Phase 2 Study
SCD Therapeutics Conference, 2016

Modus colleagues presented our story at the 5th Annual Sickle Cell Disease Therapeutics conference in New York in October

Poster presented at ASH 2016
La Biotech Interview with Modus

Learn more about our study in the Middle East